Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

NCT00063778
View directory record Official record
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 20, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335
View directory record Official record
Conditions
HIV, Substance Use Disorder (SUD), Injection Drug Use
Interventions
APRETUDE (cabotegravir)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Withdrawn Phase 1 Interventional

Dendritic Cell Vaccine for Head and Neck Cancer

NCT00492947
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
dendritic cell vaccine
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

NCT01644149
View directory record Official record
Conditions
Influenza Prophylaxis
Interventions
Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine
Device · Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 20, 2026, 1:21 AM EDT
Not listed Phase 1 Interventional

Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

NCT00767949
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
iSONEP
Biological
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

NCT05154955
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

NCT01969435
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin
Interventions
Carmustine, Etoposide phosphate, Cytarabine, Melphalan HCl (propylene glycol-free)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Early Phase 1 Interventional

Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population

NCT01382771
View directory record Official record
Conditions
Low Back Pain
Interventions
Intra-articular corticosteroid injection, Intra-articular saline injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

NCT03417284
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 20, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184
View directory record Official record
Conditions
CMV Infection
Interventions
Artesunate, Ganciclovir (GCV)
Drug
Lead sponsor
Amivas Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

NCT01834586
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anesthetic Topical Adhesive Synera
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies

NCT00456872
View directory record Official record
Conditions
Pain
Interventions
lidocaine
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

NCT01053312
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Phase I Study of G3139 Subcutaneous in Solid Tumors

NCT00543231
View directory record Official record
Conditions
Tumors
Interventions
G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2007 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Kanglaite Injection Phase I Study

NCT00031031
View directory record Official record
Conditions
Solid Tumors Refractory To Standard Therapy, Neoplasms
Interventions
Kanglaite Injection (KLT)
Drug
Lead sponsor
KangLaiTe USA
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 4 Interventional

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031
View directory record Official record
Conditions
Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
Interventions
Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment, Off-site HCV evaluation and treatment
Drug · Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 20, 2026, 1:21 AM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety Study of Cosmetic Tissue Augmentation in People of Color

NCT01147172
View directory record Official record
Conditions
Wrinkles
Interventions
Elevess
Device
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease

NCT03043742
View directory record Official record
Conditions
Chronic Ischemic Heart Disease
Interventions
Bone Marrow Derived Autologous CD133+ Selected Cell Product
Drug
Lead sponsor
Michael Sekela
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 20, 2026, 1:21 AM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 20, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 20, 2026, 1:21 AM EDT